<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065503</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201902202</org_study_id>
    <secondary_id>OCR26142</secondary_id>
    <secondary_id>AGR00015606</secondary_id>
    <nct_id>NCT04065503</nct_id>
  </id_info>
  <brief_title>Probiotic Detection and Persistence Study</brief_title>
  <official_title>Detection and Persistence of a Product Containing L. Helveticus R-0052, L. Casei HA-108, B. Breve HA-129, B. Longum R-0175 and S. Thermophilus HA-110 in Healthy Adults: an Open-label Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lallemand Health Solutions, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this study are to determine how long it takes for the strains of a probiotic&#xD;
      formulation to be detected in feces after the start of an intervention, how long they persist&#xD;
      after the end of the intervention, and the associations between detection and persistence&#xD;
      with total gut transit time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 10-week interventional, open-label pilot study designed to evaluate the detection&#xD;
      and persistence of L. helveticus R-0052, L. casei NI319, B. breve NI337, and B. longum R-0175&#xD;
      strains in feces of healthy adults following the start and the end of IP intervention,&#xD;
      respectively. This study will have an initial baseline period (4 weeks), a probiotic&#xD;
      intervention (2 weeks) and a washout period (4 weeks). Participants will complete daily&#xD;
      questionnaires regarding stool frequency, time of stool collections, and IP intake. A weekly&#xD;
      Gastrointestinal Symptom Rating Scale (GSRS) questionnaire will be administered. Transit time&#xD;
      will be assessed using radiopaque markers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">February 26, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in time to detection of probiotic strains</measure>
    <time_frame>Day 1; Day 2; Day 3, Day 4, Day 7, Day 10</time_frame>
    <description>using strain-specific qPCR assays.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in time to non-detection (persistence) of probiotic strains</measure>
    <time_frame>Day 14, Day 15, Day 16, Day 17, Day 18, Day 21, Day 24, Day 28, Day 35, Day 42</time_frame>
    <description>using strain-specific qPCR assays.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole gut transit time</measure>
    <time_frame>Day 1, Day 2, Day 3, Day 4</time_frame>
    <description>Whole gut transit time measured by radiopaque marker recovery in intervention stools</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy adults will be given probiotic strains to evaluate the detection and persistence of the strains in the participant's feces.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic Strains</intervention_name>
    <description>A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.</description>
    <arm_group_label>Healthy Adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults â‰¥ 18 to &lt; 55 years of age.&#xD;
&#xD;
          -  Habitually produces at least one bowel movement per day.&#xD;
&#xD;
          -  Willingness to maintain their usual diet and exercise patterns throughout the study.&#xD;
&#xD;
          -  Able to provide written informed consent in English.&#xD;
&#xD;
          -  Willing to provide stools and complete questionnaires, records, and diaries associated&#xD;
             with the study and to complete all study visits.&#xD;
&#xD;
          -  Willingness to discontinue consumption of probiotics and fermented products (e.g.&#xD;
             yogurts, kombucha, fermented pickles and other fermented foods with live, active&#xD;
             cultures) and probiotic supplements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Elite athletes or long-distance runners.&#xD;
&#xD;
          -  Concurrent consumption of fermented foods or probiotics. However, individuals will be&#xD;
             eligible for participation after a four (4) week wash-out period.&#xD;
&#xD;
          -  Known to be pregnant (self-disclosure) or breastfeeding or planning on becoming&#xD;
             pregnant in the next 2 months.&#xD;
&#xD;
          -  Use of antibiotic drugs (e.g., neomycin, rifaximin) within 1 month of the screening&#xD;
             visit. The screened participant would be eligible to participate four (4) weeks after&#xD;
             completing their course of antibiotics (washout period).&#xD;
&#xD;
          -  Use of other investigational products within 3 months of the screening visit.&#xD;
&#xD;
          -  Previously or are currently being treated for any previously or currently being&#xD;
             treated for any intestinal disease or condition such as IBS, Crohn's disease,&#xD;
             ulcerative colitis, celiac disease, or gastrointestinal cancer.&#xD;
&#xD;
          -  Immune disorders or with possible immune deficient status (e.g. due to surgery).&#xD;
&#xD;
          -  Milk or soy allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wendy Dahl</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Food Science and Human Nutrition Department</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>gut transit time</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

